Financial Ratios Arcus Biosciences, Inc.
Equities
RCUS
US03969F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.72 USD | -2.66% | -8.18% | -17.70% |
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -23.2 | -15.92 | 2.87 | -11.92 | -17.42 | |||
Return on Total Capital | -27.81 | -22.7 | 4.59 | -20.16 | -31.25 | |||
Return On Equity % | -42.48 | -36.89 | 7.86 | -35.62 | -54.87 | |||
Return on Common Equity | -42.48 | -36.89 | 7.86 | -35.62 | -54.87 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | -423.21 | -105.57 | 33.05 | -157.14 | -190.6 | |||
SG&A Margin | 168.19 | 54.7 | 18.88 | 92.86 | 100 | |||
EBITDA Margin % | -567.54 | -156.21 | 15.17 | -244.64 | -283.76 | |||
EBITA Margin % | -591.39 | -160.27 | 14.17 | -250 | -290.6 | |||
EBIT Margin % | -591.39 | -160.27 | 14.17 | -250 | -290.6 | |||
Income From Continuing Operations Margin % | -564.73 | -158.49 | 13.8 | -238.39 | -262.39 | |||
Net Income Margin % | -564.73 | -158.49 | 13.8 | -238.39 | -262.39 | |||
Net Avail. For Common Margin % | -564.73 | -158.49 | 13.8 | -238.39 | -262.39 | |||
Normalized Net Income Margin | -352.96 | -99.55 | 8.92 | -148.44 | -160.79 | |||
Levered Free Cash Flow Margin | -273.79 | 49.89 | -168.41 | 546.21 | -160.47 | |||
Unlevered Free Cash Flow Margin | -273.79 | 49.89 | -168.37 | 547.32 | -159.4 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.06 | 0.16 | 0.32 | 0.08 | 0.1 | |||
Fixed Assets Turnover | 1.47 | 4.71 | 4.76 | 0.82 | 0.84 | |||
Receivables Turnover (Average Receivables) | - | 131.27 | 1.03 | 0.29 | 3.04 | |||
Short Term Liquidity | ||||||||
Current Ratio | 8.49 | 6.05 | 7.6 | 5.53 | 4.52 | |||
Quick Ratio | 8.3 | 6 | 7.55 | 5.45 | 4.35 | |||
Operating Cash Flow to Current Liabilities | -3.24 | 0.91 | -1.54 | 2.27 | -1.66 | |||
Days Sales Outstanding (Average Receivables) | - | 2.79 | 355.41 | 1.28K | 120.11 | |||
Average Days Payable Outstanding | 18.15 | 23.41 | 18.47 | 19.01 | 19.86 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | - | 3.61 | 13.89 | 18.26 | 26.19 | |||
Total Debt / Total Capital | - | 3.48 | 12.2 | 15.44 | 20.75 | |||
LT Debt/Equity | - | 3.03 | 13.89 | 17.81 | 23.81 | |||
Long-Term Debt / Total Capital | - | 2.93 | 12.2 | 15.06 | 18.87 | |||
Total Liabilities / Total Assets | 19.33 | 34.96 | 47.14 | 51.15 | 57.81 | |||
EBIT / Interest Expense | - | - | 208.65 | -140 | -170 | |||
EBITDA / Interest Expense | - | - | 251.89 | -128 | -157.5 | |||
(EBITDA - Capex) / Interest Expense | - | - | 151.59 | -131 | -169.5 | |||
Total Debt / EBITDA | - | -0.15 | 1.78 | -0.47 | -0.38 | |||
Net Debt / EBITDA | 2.21 | 6.01 | -5.84 | 3.98 | 2.37 | |||
Total Debt / (EBITDA - Capex) | - | -0.15 | 2.97 | -0.46 | -0.36 | |||
Net Debt / (EBITDA - Capex) | 2.16 | 5.86 | -9.7 | 3.89 | 2.2 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 79.58 | 416.78 | 393.93 | -70.76 | 4.46 | |||
Gross Profit, 1 Yr. Growth % | 53.73 | 28.91 | -254.63 | -239.68 | 26.7 | |||
EBITDA, 1 Yr. Growth % | 66.29 | 42.23 | -147.97 | -572.41 | 21.17 | |||
EBITA, 1 Yr. Growth % | 61.7 | 40.05 | -143.67 | -618.52 | 21.43 | |||
EBIT, 1 Yr. Growth % | 61.7 | 40.05 | -143.67 | -618.52 | 21.43 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 70.81 | 45.03 | -143 | -603.77 | 14.98 | |||
Net Income, 1 Yr. Growth % | 70.81 | 45.03 | -143 | -603.77 | 14.98 | |||
Normalized Net Income, 1 Yr. Growth % | 66.68 | 45.76 | -144.26 | -583.64 | 13.16 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | 34.92 | 16.02 | -131.66 | -622.54 | 11.86 | |||
Accounts Receivable, 1 Yr. Growth % | - | 694.7 | 70.88K | -94.77 | -2.56 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | -16 | 152.82 | 482.6 | -1.46 | 5.93 | |||
Total Assets, 1 Yr. Growth % | -26.12 | 280.23 | 106.13 | -15.52 | -18.59 | |||
Tangible Book Value, 1 Yr. Growth % | -30.26 | 206.58 | 67.52 | -21.97 | -29.68 | |||
Common Equity, 1 Yr. Growth % | -30.26 | 206.58 | 67.52 | -21.97 | -29.68 | |||
Cash From Operations, 1 Yr. Growth % | 70.86 | -251.33 | -330.43 | -271.09 | -169.86 | |||
Capital Expenditures, 1 Yr. Growth % | -48.57 | 58.7 | 753.62 | -76.92 | 300 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 49.23 | -194.17 | -1.69K | -194.88 | -130.69 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 49.23 | -194.17 | -1.69K | -195.08 | -130.42 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 225.82 | 204.63 | 405.23 | 19.83 | -44.73 | |||
Gross Profit, 2 Yr. CAGR % | 17.72 | 40.77 | 41.18 | 47.41 | 33.04 | |||
EBITDA, 2 Yr. CAGR % | 29.42 | 53.79 | -17.39 | 50.48 | 139.25 | |||
EBITA, 2 Yr. CAGR % | 28.84 | 50.49 | -21.8 | 50.27 | 150.92 | |||
EBIT, 2 Yr. CAGR % | 28.84 | 50.49 | -21.8 | 50.27 | 150.92 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 26.33 | 57.39 | -21.03 | 47.33 | 140.68 | |||
Net Income, 2 Yr. CAGR % | 26.33 | 57.39 | -21.03 | 47.33 | 140.68 | |||
Normalized Net Income, 2 Yr. CAGR % | 26.33 | 55.87 | -19.68 | 47.06 | 133.94 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -74.2 | 25.11 | -39.39 | 28.57 | 141.77 | |||
Accounts Receivable, 2 Yr. CAGR % | - | - | 7.41K | 509.74 | -77.42 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | -8.85 | 45.73 | 283.79 | 139.23 | 2.17 | |||
Total Assets, 2 Yr. CAGR % | 3.26 | 67.6 | 179.96 | 31.97 | -17.07 | |||
Tangible Book Value, 2 Yr. CAGR % | 50.51 | 46.22 | 126.62 | 14.37 | -25.93 | |||
Common Equity, 2 Yr. CAGR % | 50.51 | 46.22 | 126.62 | 14.37 | -25.93 | |||
Cash From Operations, 2 Yr. CAGR % | 71.22 | 60.8 | 86.74 | 98.64 | 9.33 | |||
Capital Expenditures, 2 Yr. CAGR % | -40.91 | -9.66 | 268.06 | 41.42 | -3.92 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 19.01 | 18.55 | 296.24 | 287.56 | -46.04 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 19.01 | 18.55 | 296.19 | 287.95 | -46.22 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % |